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This prospective, multicenter phase I/II study of unmanipulated HLA-haploidentical reduced-intensity stem
cell transplantation using a low dose of antieT lymphocyte globulin (ATG) and steroid was conducted in 5
institutions in Japan. Thirty-four patients with hematologic malignancies whowere in an advanced stage or at a
high risk of relapse at the time of transplantation were enrolled. Among them, 7 patients underwent trans-
plantation as a second transplantation because of relapse after the previous allogeneic stem cell transplantation.
The conditioning regimen consisted of ﬂudarabine, busulfan, and ATG (Fresenius, 8 mg/kg), and graft-versus-
host disease (GVHD) prophylaxis consisted of tacrolimus and methylprednisolone (1 mg/kg). All patients
except 1 (97.1%) achieved donor-type engraftment. Rapid hematopoietic engraftment was achieved, with
neutrophils > .5  109/L on day 11 and platelets > 20  109/L on day 17.5. Treatment was started for grade I
GVHD, and the cumulative incidences of acute grade I and grade II to IV GVHD were 27.5% and 30.7%,
respectively. The incidence of chronic GVHD (extensive type) was 20%. Fourteen patients (41.2%) had a relapse.
The cumulative incidence of transplantation-related mortality at 1 year after transplantation was 26.5%.
The survival rate at day 100 was 88.2%. The survival rates at 1 year for patients with complete remission
(CR)/chronic phase (n ¼ 8) and non-CR (n ¼ 26) status before transplantation were 62.5% and 42.3%, respec-
tively. In the multivariate analysis, non-CR status before transplantation was the only factor signiﬁcant
prognostic factor of increased relapse (P ¼ .0424), which tended to be associated with a lower survival rate
(P ¼ .0524). This transplantation protocol is safe and feasible, if a suitable donor is not available in a timely
manner. As the main cause of death was relapse and not GVHD, more intensiﬁed conditioning or attenuation of
GVHD prophylaxis and/or donor lymphocyte infusion may be desirable for patients with non-CR status.
 2015 American Society for Blood and Marrow Transplantation.dgments on page 1504.
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ty for Blood and Marrow Transplantation.INTRODUCTION
Bone marrow transplantation (BMT) from siblings geno-
typically matched for HLA improves long-term survival in
patients with hematologic malignancies [1]. However, more
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do not have a matched sibling donor. For these patients,
unrelated bone marrow (BM) or peripheral blood (PB) do-
nors or umbilical cord blood units are now available; how-
ever, these stem cell sources have the drawbacks of requiring
long-term coordination and having a high rate of graft
rejection. In this regard, HLA-haploidentical family donors
have recently been in the spotlight as the fourth stem
cell source because the likelihood of identifying an HLA-
haploidentical donor in a family is over 90%.
Themajordrawback ofHLA-haploidentical transplantation
is graft-versus-host disease (GVHD); however, several
clinical approacheshave recently beendeveloped to overcome
it. One successful approach is to use T celledepleted
grafts, with a megadose of CD34þ cells [2,3] or CD3þ/CD19þ
celledepleted grafts [4]. Another approach is unmanipulated
HLA-haploidentical transplantation using a relatively high
dose of antieT lymphocyte globulin (ATG) after myeloa-
blative [5] or reduced-intensity conditioning (RIC) treatment
[6]. Furthermore, the most recent approach is the post-
transplantation cyclophosphamide method [7-9], in which
a high dose of cyclophosphamide administered a few days
after transplantation was reported to induce bidirectional
(in graft-versus-host [GVH] and host-versus-graft directions)
tolerance. These transplantation procedures may be useful
for the achievement of donor engraftment and immunolog-
ical tolerance; however, graft-versus-leukemia (GVL) effects
have not seemed to be sufﬁciently strong to prevent disease
relapse.
WehavebeenstudyingunmanipulatedHLA-haploidentical
reduced-intensity stem cell transplantation (RIST) by the
combination of a low dose of ATG and GVHD prophylaxis
consisting of tacrolimus and methylprednisolone (mPSL), and
we reported the outcome of a pilot study, in which rapid and
stable engraftment with complete donor chimerism, a low
incidence of acute severe GVHD, and relatively strong GVL ef-
fects were observed [10-12]. For patients in an advanced stage
or noncomplete remission state, to prevent relapse after
transplantation, we considered it important to utilize a strong
allogeneic response of unmanipulated haploidentical grafts.
Our concept is to use a low dose of ATG (one third or one
quarter of the usual dose) coupledwith the use of steroid. This
combination of such a low dose of ATG and prophylactic use of
steroid may induce GVH reaction under a low-inﬂammatory
cytokine milieu, leading to the realization of a GVL effect not
accompanied by GVHD, the goal of allogeneic stem cell trans-
plantation (SCT).
In the present study, we performed a prospective multi-
center phase I/II study in patients with hematologic malig-
nancies in an advanced stage or at high risk of relapse to
elucidate the safety and feasibility of our regimen.PATIENTS AND METHODS
Patients
Patients with advanced hematologic malignancies or at a high risk of
relapse were enrolled in this prospective study, which consisted of phase I
and II. Eligibility criteria in terms of disease and disease status were as
follows: (1) chronic myeloid leukemia in second or later chronic phase (CP),
accelerated phase, blast crisis, or relapse after allogeneic SCT; (2) acute
myeloid leukemia in second or later complete remission (CR), induction
failure, non-CR, or relapse after allogeneic SCT; (3) acute lymphoid leukemia
(ALL) in second or later CR, induction failure, non-CR, relapse after allogeneic
SCT, or ﬁrst CR with positive test for BCR-ABL mRNA of Philadelphia chro-
mosomeepositive ALL; (4) myelodysplastic syndrome in the intermediate II
or high-risk groups of the International Prognostic Scoring System; and (5)
malignant lymphoma in a non-CR state after conventional chemotherapy or
autologous SCT. For chronic myeloid leukemia, acute myeloid leukemia, andALL, cases with blast cells > 30% were ineligible. The subjects consisted of
adult patients ages 35 to 60 years or younger patients ages 18 to 35 years
who were considered ineligible for myeloablative preparative regimens
because of comorbidities. Patients were not eligible for transplantation if
they had severe liver, renal, heart, or lung disease, as follows: total bilirubin
level over 2.0 mg/dL or aspartate aminotransferase (AST) > 2.5 times the
normal upper limit, serum creatinine level over 1.5 times the normal upper
limit, ejection fraction< 50% in echocardiogram or oxygen saturation< 93%
on room air. Patients who had an HLA-identical or 1 antigen-mismatched
related donor in the family were not eligible. Patients who had an HLA-
identical or HLA 1 alleleemismatched donor (in HLA-A, -B, and -DR loci)
in the Japan Marrow Donor Program were not eligible; however, they were
eligible if they urgently needed transplantation.
Exclusion criteria included a past history of allergy to the drugs used in
this study, positivity for the surface antigen of the hepatitis B virus and/or
antiehuman immunodeﬁciency virus antibody, presence of active central
nervous system lesion and presence of active infectious lesions. Written
informed consent was obtained from all of the patients or their families,
including the donors. The protocol was approved by the institutional review
board of each of the participating institutions. The treatment protocol was
listed on the University Hospital Medical Information Network Clinical Trials
Registry at www.umin.ac.jp/icdr/index.html as UMIN C000000403.
Regimens
The conditioning regimen consisted of ﬂudarabine at 30mg/m2/day for 6
days (days10 to5), oral busulfanat 4.0mg/kg/day (or intravenousbusulfan
at 3.2mg/kg/day) for 2 days (days6 to5) and rabbit ATG (Fresenius Biotech
Gräfelﬁng, Gräfelﬁng, Germany) at 2mg/kg/day for 4 days (days4 to1). For
patients who had leukemia cells> 10% in the PB and/or BM, cytarabine at 2 g/
m2 for 4 days (days 10 to 7) was added to the conditioning regimen to
reduce the tumor burden. To prevent the anaphylaxis caused by ATG, mPSL
was administered at 1 mg/kg on days 4 to 1 and thereafter continued as
GVHD prophylaxis at the same dose. PB stem cell (PBSC) mobilization using
granulocyte colonyestimulating factor (G-CSF) was performed as described
previously [10]. Basically, 2 leukapheresis procedureswereperformedondays
4 and 5 of G-CSF administration. T cell depletion was not performed. PBSCs
were frozen for 17 patients andwere freshly transplanted ondays0 andþ1 for
the remaining 17 patients. After transplantation, patients receivedG-CSF from
day 5 to the day of neutrophil engraftment if the absolute neutrophil count
(ANC) dropped to<.5109/L. GVHD prophylaxis consisted of tacrolimus and
mPSL. Intravenous administration of mPSL was started at a dose of 1 mg/kg/
day divided twice a day fromday 0. Continuous intravenous administration of
tacrolimus was started at a dose of .02 mg/kg/day from day 2. The target
blood concentration of tacrolimuswas set at 10 to 15 ng/mL up to day 20, 8 to
12 ng/mL on days 20 to 30, and thereafter tapered in the absence of acute
GVHD. Patients received intravenous tacrolimus therapy until they could
reliably receive oralmedications after transplantation. At that time, theywere
switched to an oral dose calculated to be 4 times their current intravenous
dose. The oral dose was administered in 4 divided doses every 6 hours. The
dose reductionofmPSLwas startedonday15andperformed relatively rapidly
until day 30 (the target dose on day 30 was .5 mg/kg/day) and was thereafter
carefully continued.
Conﬁrmation of Donor Engraftment
The conﬁrmation of donor engraftment after transplantation was
mainly determined by polymerase chain reaction ampliﬁcation of infor-
mative microsatellite regions, which identiﬁed the difference between
donor and recipient (based on polymorphisms found in pretransplantation
donor/recipient samples) [10]. For sex-mismatched transplantation, donor
engraftment was also conﬁrmed by XY ﬂuorescence in situ hybridization.
Diagnosis and Treatment of GVHD
Acute GVHD was graded according to standard criteria [13]. Diagnosis
and grading of chronic GVHD followed the Seattle criteria [14]. When
GVHD (grade I) was diagnosed, the steroid dose was increased (mPSL at
2 mg/kg/day at the maximum dose) depending on the severity of GVHD, and
mycophenolate mofetil was started at a dose of 15 mg/kg/day. When GVHD
was resistant to these treatments, ATG and/or antitumor necrosis factor-a
antibody (inﬂiximab, Johnson & Johnson, New Brunswick, NJ) at 10 mg/kg
were administered.
Supportive Care
Each patient was isolated in a laminar air-ﬂow room or protective
environment room, and standard decontamination procedures were fol-
lowed. Other supportive therapies were performed as previously described
[10].
Detection of cytomegalovirus (CMV) antigenemia was performed using
an immunoperoxidase-conjugated monoclonal antibody, HRP-C7, which
Table 1
Patient Characteristics
Characteristic Value
Number of patients 34
Sex: male/female 22/12
Age, median (range), yr 51 (32-60)
Disease
AML/MDS 18
ALL 6
Lymphoma 9
Others 1
Disease status
Low (CR/RA/CP) 8
Intermediate (PR/RAEB/AP) 3
High 23
Donor
Offspring 25
Sibling 7
Parent 1
Others 1
HLA disparity in GVH direction
Two antigens 20
Three antigens 14
Number of transplantations
First 27
Second 7
Grafts
Frozen 17
Nonfrozen 17
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome;
RA, refractory anemia; PR, partial remission; RAEB, refractory anemia with
excess blasts; AP, accelerated phase.
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antigenemia was expressed as the number of CMV antigenepositive cells
per 50,000 leukocytes. pp65 antigen testing in PB was performed once
weekly.
The functional impairment of the patients at day 100 was assessed by
Karnofsky performance rating.
Primary and Secondary Endpoints
The primary endpoint of phase I was donor-type engraftment within
day 35 after the time of the transplantation and that of phase II was survival
at day 100 after transplantation. Secondary endpoints of the phase I/II study
were the incidence and severity of acute and chronic GVHDs, overall sur-
vival, transplantation-related mortality (TRM) within 1 year after trans-
plantation, incidence of infections, and immunological recovery.
Statistics
Because the phase I objective was to evaluate whether the regimen
could provide donor-type engraftment or not, as well as determine safety
and feasibility, for the present, we planned to enroll 10 patients. In the
previous retrospective single-center study using the same regimen, donor-
type engraftment was achieved in 24 out of 25 (96%) patients [10]. There-
fore, when donor-type engraftment was achieved in more than 8 patients,
we decided to go to phase II. For the primary endpoint of phase II (survival at
day 100 after the transplantation), 32 patients were required for the ex-
pected survival proportion at day 100 of .85, with the width of 95% conﬁ-
dence interval being .125. Assuming a dropout rate of few patients,
35 patients were required.
Continuous and categorical data are summarized as medians with
ranges and frequencies, respectively. The cumulative probability curves of
neutrophil and platelet recovery and of overall survival were estimated with
the use of the Kaplan-Meier product-limit method. Overall survival curves
were compared using the log-rank test. The cumulative incidence curves of
acute GVHD, relapse, and TRM were estimated with the use of the cumu-
lative incidence function, which accounted for death and relapse, TRM, and
relapse, as a competing risk, respectively. The cumulative incidence curves
were compared using Gray’s test [16]. To examine effects of the following
prognostic factors on GVHD, relapse, TRM, survival and event-free survival
(EFS), univariate and multivariate analyses were performed with the use of
the Cox proportional-hazards model: donor source, age, disease status
before transplantation, sex, number of transplantations, HLA disparity in the
GVH direction, CD34 dose, and use of frozen or fresh PBSCs. All tests of
signiﬁcance were 2 sided, and P values less than .05 were considered to
indicate statistical signiﬁcance. Statistical analyses were performed with
EZR (Saitama Medical Centre, Jichi Medical University, Saitama, Japan;
http://www.jichi.ac.jp/saitama-sct/SaitamaHP.ﬁles/statmedEN.html), which
is a graphical user interface for R (The R Foundation for Statistical
Computing, Vienna, Austria, version 2.13.0) [17,18] .
RESULTS
Primary Endpoints of Phase I and II Studies
This prospective phase I/II study was performed in 5
transplantation institutions in Japan between 2006 and
2011. The primary endpoint of phase I was donor-type
engraftment within 35 days after the time of the trans-
plantation. As described in Patients and Methods, 10 pa-
tients were enrolled in phase I, and all of them achieved
rapid donor-type engraftment, with neutrophil engraftment
(ANC > .5  109/L) at a median of 12 days (range, 10 to
15 days) and platelet engraftment at a median of 15.5 days
(range, 11 to 41 days) after transplantation.
Therefore, we proceeded to phase II. The primary
endpoint of phase II was the survival rate at 100 days after
transplantation. One patient in the phase II trial did not
match the inclusion criteria after enrollment and was
excluded from this study. Thus, data from a total of 34 pa-
tients were analyzed. Thirty of the 34 (88.2%) patients sur-
vived at 100 days after transplantation.
Patients’ Characteristics
In the following data analysis in detail, we analyzed
data from 34 patients who were enrolled in phase I and
phase II. Patients (22 males and 12 females) who had
hematologic malignancies underwent unmanipulatedhaploidentical RIST. The median age of the patients was 51
years (range, 32 to 60). The patients’ characteristics are
shown in Table 1. Donors were offspring (n ¼ 25), siblings
(n ¼ 7), a mother (n ¼ 1), and a nephew (n ¼ 1). For disease
status before transplantation, 8 patients were at low risk (CR/
refractory anemia/CP), 3 at intermediate risk (partial remis-
sion/refractory anemiawith excess blasts/accelerated phase),
and 23 at high risk (non-CR/blast crisis). Eight patients
underwent transplantation in a CR/CP state: 2 patients in
CR1, 5 in CR2, and 1 in CP2. Seven patients were enrolled for a
second allogeneic transplantation because of relapse after
the previous allogeneic SCT.Engraftment
All patients received PBSCs containing a median of
4.26  106 (range, 1.57 to 12.0  106) CD34þ cells/kg and a
median of 1.22  108 (range, .12 to 3.40  108) CD3þ cells/kg,
without Tcell depletion. All patients except 1 (97.1%) achieved
donor engraftment. Among the 33 patients achieving donor
engraftment, ANC did not decrease to below .5  109/L in 1
patient. The remaining 32 patients achieved neutrophil
engraftment (ANC> .5109/L) at amedianof 11days (range, 8
to 17 days) after transplantation (Figure 1). Among the 33 pa-
tients who achieved donor hematopoietic engraftment, 3 pa-
tients had no platelet recovery because of relapse or
transplantation-related complications. The platelet count
did not decrease to below 20  109/L in 4 patients, and these
patientshadnoneed forplatelet transfusion.The remaining26
patients achieved an unsupported platelet count of 20 109/L
at a median of 17.5 days (range, 11 to 41 days) (Figure 1).Lymphocyte Recovery and CMV Antigenemia
Lymphocyte recovery could be analyzed in 14 patients.
The CD4þ T cell count recovered slowly, with the median cell
count exceeding 49 106/L at 9months and 240 106/L at 18
Figure 1. Donor hematopoietic reconstitution. Thirty-three out of the 34 patients achieved donor-type engraftment. The cumulative percentages of patients who
achieved ANC > .5  109/L and of patients in whom platelet counts recovered to > 20  109/L are shown by solid and broken lines, respectively.
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the CD8þ T cell count recovered more rapidly (Figure 2B).
CMV antigenemia was observed in 32 patients (94%).
The median peak number of CMV antigenepositive leu-
kocytes was 20.2 per 50,000 WBCs, with a range of .5 to
565 per 50,000. The median time when the number of
CMV antigenepositive leukocytes peaked was day 38, with
a range from day 12 to 125. One patient developed CMV
retinitis, which was successfully treated by ganciclovir.
CMV antigenemia in the remaining patients could be
controlled by the administration of ganciclovir and/or
foscarnet.
Other Adverse Events
Other adverse events are shown in Table 2. Three pa-
tients developed bacterial pneumonia: 2 sepsis and 1
invasive aspergillosis. Four patients developed herpes
zoster and 1 CMV retinitis. Eight patients (23.5%) devel-
oped virus-associated hemorrhagic cystitis. In all cases, the
causal virus was identiﬁed by the PCR method for the vi-
ruses: BK virus (6 cases), and adenovirus and BK virus (2
cases). Among them, 2 patients developed lethal adeno-
virus pneumonia.
GVHD
In the present study, treatment was started for all grades
of GVHD, including grade I GVHD, as GVHD after unmanip-
ulated haploidentical SCT tends to progress rapidly. Fourteen
(42.4%) of the 33 patients who achieved donor engraftment
did not develop acute GVHD. Ten patients developed severe
GVHD (grade II): 3 patients developed grade II, 5 developed
grade III, and 2 developed grade IV GVHD. The proﬁles of
acute GVHD (grade II) are detailed in Table 3.
The cumulative incidence of severe (grade II to IV) GVHD
was 30.7% (95% conﬁdence interval [CI], 15.8% to 47.0%)(Figure 3A). Although patients receiving nonfrozen grafts
(n ¼ 17) tended to develop severe GVHD earlier (at a median
of 30 days [range, 27 to 36 days]) than those receiving frozen
grafts (n ¼ 16, at a median of 73 days [range, 20 to 97 days]),
there was no signiﬁcant difference in the cumulative inci-
dence of GVHD between the 2 groups (Figure 3B, Table 4). In
the univariate analysis, HLA 2 antigen versus 3 antigen
mismatch in the GVH direction also had no impact on the
occurrence of GVHD. Patients younger than 52 years tended
to have a higher risk of GVHD (P ¼ .0934). In the multivariate
analysis, there was no signiﬁcant prognostic factor of acute
GVHD.
Nine patients developed grade I GVHD and all of them
had skin-only GVHD. For one of the patients, the grade I
GVHD subsided without therapeutic interventions. For the
remaining 8 patients, the GVHD was completely controlled
after the following treatments: 4 patients received an in-
crease in mPSL to a dose of up to 2 mg/kg, 2 received
an increase in mPSL dose to .5 mg/kg, 1 received an increase
in tacrolimus dose, and 1 added mycophenolate mofetil
10 mg/kg. The cumulative incidence of grade I GVHD was
27.5% (95% CI, 13.5% to 43.6%) (Figure 3C).
For chronic GVHD, among 30 patients who survived for
more than 100 days, 6 (20%) developed extensive GVHD: 2
patients had skin lesion alone; 1 eye lesion alone; 1 skin
and mouth lesions; 1 skin, mouth, and liver lesions; and 1
skin and liver lesions, with pleural effusion. Among them, 1
patient died of uncontrollable pleural effusion. In 10
(52.6%) of the 19 patients who survived for more than 100
days without developing chronic GVHD and who did not
have a relapse, immunosuppressants could be tapered off
at a median of 136.5 days (range, 24 to 1196 days) after
transplantation. The remaining surviving patients still
need a small dose of tacrolimus and prednisolone at a
median dose of 4 mg/day (range, 3 to 7 mg/day).
Figure 2. T lymphocyte recovery after transplantation. (A) CD4þ cells and (B) CD8þ cells. Horizontal bars indicate median values.
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Fourteen (41.2%) patients had a relapse, which occurred
at a median of 97 days (range, 15 to 437 days) after trans-
plantation. Ten patients had a relapse in BM, and the
remaining 4 had an extramedullary relapse (central nervous
system, eye, skin, and iliac bone). Among them, 2 patients
are alive in CR (on days 1583 and 2450); 1 underwent
haploidentical RIST using a graft from another donor and the
other received a donor lymphocyte infusion (DLI) with
chemotherapy. Patients with non-CR status before trans-
plantation tended to have a higher risk of relapse than those
with CR/CP status (Gray’s test, P ¼ .0843). The cumulativeincidence of relapse at 1 year was 42.3% (95% CI, 22.8% to
60.6%) for patients with non-CR and 12.5% (95% CI, .5% to
44.5%) for those with CR/CP (Figure 4). In the multivariate
analysis, non-CR status before transplantation signiﬁcantly
increased the relapse rate compared with CR/CP status
(P ¼ .0424) (Table 4).
The cumulative incidence of TRM at 1 year was 26.5%
(95% CI, 12.9% to 42.2%). There was no signiﬁcant differ-
ence in the incidence of TRM between patients with CR/CP
and non-CR before transplantation (P ¼ .329) (Figure 5).
In the univariate analysis, no factors, including age, disease
status, HLA disparity in the GVH direction, donor other
Table 2
Adverse Events (n ¼ 34)
Event n (%)
Infections
Bacteria
Pneumonia 3 (8.8)
Bacteremia 2 (5.9)
Fungus 1 (2.9)
Pneumocystis jirovecii 1 (2.9)
Virus
CMV 1 (2.9)
Herpes zoster 4 (11.8)
Virus-associated hemorrhagic cystitis 8 (23.5)
Stomatitis 7 (20.6)
FK506 encephalopathy 1 (2.9)
Thrombotic microangiopathy 1 (2.9)
Thrombocytic thrombocytopenic purpura 1 (2.9)
Hepatic venoocclusive disease 0 (0)
Liver dysfunction 3 (8.8)
Paralytic ileus 1 (2.9)
Nephrotoxicity 2 (5.9)
Hepatitis B 1 (2.9)
Encephalitis 1 (2.9)
Cerebral hemorrhage 1 (2.9)
Optic neuritis 1 (2.9)
Hepatic dysfunction indicates hepatic toxicities  grade 1; nephrotoxicity
indicates renal failure that needed hemodialysis; FK506 indicates
tacrolimus.
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had a signiﬁcant impact on the occurrence of TRM
(Table 4).
The main cause of death was disease relapse (n ¼ 12).
Other causes of death were invasive aspergillosis (n ¼ 2),
disseminated adenovirus infection (n ¼ 2), pneumocystis
pneumonia (n ¼ 1), acute GVHD (n ¼ 3), thrombotic micro-
angiopathy (n ¼ 1), renal failure (n ¼ 2), hepatitis B (n ¼ 1),
and chronic GVHDerelated respiratory failure with massive
pleural effusion (n ¼ 1).
Survival
The survival rate at 100 days was 88.2% (95% CI, 71.6% to
95.4%), although all patients were in non-CR or at a high risk
of relapse at the time of transplantation. Twenty-one (70%) of
the 30 patients who survived at 100 days scored 80 in
the Karnofsky performance rating. Sixteen patients (47.1%)
survived 1 year after transplantation: 14 patients were
alive with CR status and 2 patients had disease. Patients with
CR/CP had a signiﬁcantly higher survival rate than thosewith
non-CR (log-rank test, P ¼ .0305). The survival rates at 1 year
were 62.5% (95% CI, 22.9% to 86.1%) for patients with CR/CP
and 42.3% (95% CI, 23.5% to 60.0%) for those with non-CRTable 3
Proﬁle of Acute GVHD
No. Days after
Transplantation
Stage Grade Number of
Organs
Skin Gut Liver
1 20 2 3 4 4 3
2 22 1 2 0 3 2
3 27 3 1 2 3 3
4 30 0 2 2 4 2
5 33 3 1 0 2 2
6 36 0 3 0 3 1
7 55 3 0 0 2 1
8 73 1 1 2 3 3
9 76 2 3 3 3 3
10 97 1 1 0 2 2
The cases are shown in order of the time of development of GVHD.(Figure 6A). Seven patients underwent a haploidentical
RIST as second transplantation. Three patients underwent
transplantation in CR2 and 4 in non-CR. Among them, 2 pa-
tients (1 patient undergoing in non-CR and another in CR2)
were alive in CR 622 and 706 days after transplantation.
There was no signiﬁcant difference in survival between ﬁrst
and second transplantations (P ¼ .892), as shown in
Figure 6B. For patients with leukemia, the survival rates at
1 year were 71.4% (95% CI, 25.8% to 92.0%) for patients with
CR/CP and 50.0% (95% CI, 25.9% to 70.1%) for those with non-
CR (Figure 6C). In the univariate analysis, non-CR status
before transplantation signiﬁcantly decreased the survival
rate compared with CR/CP status (P¼ .0423). However, in the
multivariate analysis, there was no factor that was signiﬁ-
cantly associated with survival rate (Table 4). For EFS, in the
univariate analysis, non-CR status before transplantation and
donors other than sibling or offspring signiﬁcantly reduced
the EFS rate; however, in the multivariate analysis, only non-
CR status before transplantation was signiﬁcantly associated
with decreasing the rate of EFS (P ¼ .0145) (Table 4).DISCUSSION
The primary endpoint of phase I was donor-type
engraftment. Thirty-three (97.1%) of the 34 patients ach-
ieved rapid donor-type engraftment, with the neutrophil
engraftment occurring at a median of 11 days after trans-
plantation. The primary endpoint of phase II was survival at
day 100. Thirty (88.2%) patients survived at day 100,
although all patients underwent transplantation in non-CR
or at a high risk of relapse. The overall mortality rate at 100
days for the transplantation cohort in this study who un-
derwent transplantation in non-CR was 15.4%, which was
much better than the outcomes (39% to 41%) of a large-scale,
retrospective study that analyzed data of patients undergo-
ing allogeneic SCT in non-CR [19]. These results indicate the
safety of our haploidentical regimen, which can be applied to
patients if an HLA-matched donor is not available in a timely
manner.
In the present study, the survival rate at 3 years for pa-
tients who underwent transplantation in non-CR was 18.5%
(Figure 6A), with a 26.7% probability for patients with leu-
kemia (Figure 6C), which is in no way inferior to the out-
comes of other retrospective studies analyzing patients
undergoing related or unrelated HLA-matched SCT in non-
CR, in whom the long-term survival rate was reported to be
9% to 20% [19-21].
On the other hand, in the present study 8 patients un-
derwent haploidentical RIST in a CR/CP state because of a
high risk of relapse. The survival rate at 3 years of these
patients was 62.5% (Figure 6A), with a 71.4% probability
for patients with leukemia (Figure 6C), which is again
comparable to the outcomes of HLA-matched SCT [22,23].
Thus, various methods of noneex vivo T celledepleted
HLA-haploidentical SCT, including ours, a conventional
dose of ATG with myeloablative [5] or RIC [6] regimen, and
post-transplantation cyclophosphamide [9], seem as good
as HLA-matched SCT; however, prospectively controlled
studies evaluating donor effect in speciﬁc categories are still
lacking.
Among patients achieving donor engraftment, 10 (30.3%)
developed severe acute GVHD (grade II). The incidence of
severe GVHD was slightly higher than that in our pilot study
[10], but it was comparable to those in other studies of un-
manipulated haploidentical SCT using ATG [5].
Figure 3. Cumulative incidence of acute GVHD (grade II). (A) The cumulative incidence of acute  grade II GVHD was 30.7%. (B) The cumulative incidences of acute
GVHD for patients who received nonfrozen and frozen grafts are shown. Solid line indicates nonfrozen grafts; broken line, frozen grafts. (C) The cumulative incidence
of acute grade I GVHD was 27.5%.
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as functional impairment of nondeleted lymphocytes. For
instance, they suppress chemokine receptors on lympho-
cytes, including LFA-1, a4b7 integrin, CXCR4, and CCR7 [24],
suggesting that ATGs may contribute to blocking the homing
of activated donor Tcells to GVH target organs. The use of ATG
at a high concentration shows cytotoxic effects, nonspeciﬁ-
cally for T cells by antibody-dependent cell-mediated cyto-
toxicity (ADCC) and complement-dependent cytotoxicityTable 4
Univariate and Multivariate Analyses
Outcome Univariate Analysis
Factors Hazard
Grades II-IV
GVHD
Patient age (<52 years) 3.774
Freezing of grafts
HLA disparity (3 versus 2) in the GVH direction
Relapse Disease status (non-CR) 7.503
Blasts in PB
HLA disparity (3 versus 2) in the GVH direction
Number of transplantations (ﬁrst versus second or later)
Survival Disease status (non-CR) 3.523
Donor (other than sibling or offspring) 3.723
EFS Disease status (non-CR) 4.907
Donor (other than sibling or offspring) 4.555
NS indicates not signiﬁcant.(CDC)activities, but at a lowconcentration, use ofATG induces
apoptosis preferentially to activated T cells through the Fas-
Fas ligand [25,26]. Therefore, the use of ATG at a low dose
may have an advantage of regulating GVHD without aggra-
vating the immunosuppressive state. Furthermore, a lowdose
of ATG was recently reported to induce the generation of
regulatory T cells [27].
Regarding the ATG dose for unmanipulated hap-
loidentical SCT, a Chinese group used thymoglobulin (TMG),Multivariate Analysis
Ratio P Value Factors Hazard Ratio P Value
.0934 Patient age (<52 years) NS
NS
NS
.0531 Disease status (non-CR) 8.356 .0424
NS
NS
NS
.0423 Disease status (non-CR) 2.862 .0524
.0912 Donor (other than sibling or
offspring)
NS
.0116 Disease status (non-CR) 4.707 .0145
.0491 Donor (other than sibling or
offspring)
NS
Figure 4. Cumulative incidence of relapse. Solid and broken lines indicate patients who underwent transplantation in a CR/CP and in a non-CR state, respectively.
Relapse rates for patients at 100 days, 1 year, and 3 years were 12.5% for patients in CR/CP, and 23.1%, 42.3%, and 50% for non-CR, respectively.
K. Ikegame et al. / Biol Blood Marrow Transplant 21 (2015) 1495e15051502a rabbit ATG, at a total dose of 10 mg/kg in a myeloablative
regimen, and reported a 40% incidence of severe GVHD [5].
Furthermore, a Korean group used TMG at a total dose of 12
mg/kg and then reduced it to 9 mg/kg in a RIC treatment
consisting of ﬂudarabine, busulfan, and ATG, the same
regimen as ours; they reported a 20% incidence of severeFigure 5. Cumulative incidence of TRM. Solid and broken lines indicate patients who
cumulative incidences of TRM at 1 year and 3 years were both 25% for patients in CRGVHD [6]. We used another rabbit ATG (Fresenius: ATG-F) at
a total dose of 8 mg/kg. ATG-F and TMG both belong to rabbit
ATGs, but TMG has been reported to have more immuno-
suppressive effects than ATG-F. For unrelated HLA-matched
BMT, TMG at 7.5 to 20 mg/kg or ATG-F at 30 to 80 mg/kg
have been used [28-32], which suggests that TMG has 3 tounderwent transplantation in a CR/CP and in a non-CR state, respectively. The
/CP, and 26.9% and 38.5% for non-CR, respectively.
Figure 6. Overall survival rate. (A) Solid and broken lines indicate patients who underwent transplantation in a CR/CP and in a non-CR state, respectively; the survival
rates at day 100, 1 year, and 3 years were 100%, 62.5%, and 62.5% for patients in CR/CP, and 84.6%, 42.3%, and 18.5% for those in non-CR, respectively. (B) Solid and
broken lines indicate patients who underwent ﬁrst and second transplantations, respectively. (C) Overall survival for patients with leukemia. Solid and broken lines
indicate patients who underwent transplantation in a CR/CP and in a non-CR state, respectively; the survival rates at day 100, 1 year, and 3 years were 100%, 71.4%,
and 71.4% for patients in CR/CP, and 94.4%, 50.0% and 26.7% for those in non-CR, respectively.
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Therefore, ATG-F at 8 mg/kg used in the present study
seems to be a much lower dose than that by the Korean
group [6]. ATG-F at 8 mg/kg used as GVHD prophylaxis is not
considered to be enough to suppress GVH reaction after
haploidentical SCT. Nevertheless, the incidence of severe
acute GVHD was as low as 30.7% in the present study
(Figure 3A). Given that such a low incidence of severe GVHD
was observed, we consider that allogeneic response occurred
under the low cytokine milieu produced by prophylactic use
of steroid.
Steroids are effective in the treatment of most patients
with acute GVHD, but their use for the prophylaxis of
GVHD is controversial [33-36]. How steroids exert their
anti-inﬂammatory and immunosuppressive effects is still
incompletely understood but involves the regulation of cell
proliferation via apoptosis and kinase signaling pathways
[37,38] and regulation of the expression of proinﬂammatory
genes and cytokine pathways [39,40]. Bouazzaoui et al.
recently reported, using a murine experimental trans-
plantation model, that steroids suppressed intestinal GVHD
by reduction of the expression of adhesion molecules,
including mucosal addressin cell adhesion molecule-1 and
intercellular adhesion molecule-1, chemokines, includingCXCL9-11 and CCL 2-3, and cytokines, including interferon-g
and TNF-a, when started early after GVHD onset [41]. In
addition, if steroids suppress the production of inﬂammatory
cytokines, donor alloresponse under a low-cytokine milieu
may preserve GVL effects, as observed in the delayed DLI
study, in which DLI after the subsidence of cytokine storm
induced a GVL reaction not coupled with GVHD [42].
For chronic GVHD, in contrast to the result of the multi-
center study of unmanipulated myeloablative haploidentical
SCT that was previously conducted in Japan [43], in which
the incidence was 56.5%, the incidence of chronic extensive
GVHD in the present study was as low as 20%. The use of ATG
or/and RIC may have contributed to the low incidence of
chronic GVHD.
In the present study, themain reason for treatment failure
was relapse: 14 (41.2%) patients had a relapse, which was
the main cause of death. In the multivariate analysis, the
presence of blasts in the PB, HLA disparity in the GVH di-
rection (2 antigens versus 3 antigens), and the number of
transplantations (ﬁrst versus second transplantation) had no
signiﬁcant impact on the relapse rate. Non-CR status before
transplantation was the only factor that was signiﬁcantly
associated with increased relapse rate (Table 4). Conse-
quently, we could not show in the present study a strong
K. Ikegame et al. / Biol Blood Marrow Transplant 21 (2015) 1495e15051504antitumor effect of this regimen, as was suggested by our
previous single-center study [10], although that was not the
aim of this study. Our regimen consisting of ﬂudarabine,
busulfan, and ATG seems to be relatively weak as a condi-
tioning regimen for patients with a high tumor burden or
rapid growth tumor. We showed in the previous study [10]
using the same regimen that 100% donor T cell chimerism
was achieved on day 11 but that the granulocyte fractionwas
still composed of recipient cells alone on day 7, with a sub-
sequent rapid increase in donor components, and turned to
full donor chimerism on day 14, which may suggest that
this conditioning regimen has difﬁculty controlling rapidly
growing tumors. Thus, a more intensiﬁed preconditioning
regimen is required to reduce the relapse rate; therefore, we
have recently been using a regimen containing melphalan
instead of busulfan in haploidentical RIST for patients with
a high tumor burden. As other approaches to reduce the
relapse rate, the reduction in the dose of tacrolimus or ste-
roid used as GVHD prophylaxis, or DLI in an early stage of
relapse coupled with frequent monitoring of MRD may be
considered.
The cumulative incidence of TRM at 1 year was 26.5% (95%
CI, 12.9% to 42.2%), comparable to the outcomes of other
studies [19,44-46]. No variables, including age, disease status
before transplantation, HLA disparity in the GVH direction,
donor other than sibling or offspring, and number of trans-
plantations, were signiﬁcantly associated with the occur-
rence of TRM (Table 4).
In conclusion, the outcomes of this prospective, multi-
center trial of unmanipulated haploidentical RIST reveal
that our regimen for haploidentical RIST is safe and feasible
if a suitable donor is not available in a timely manner;
however, the use of more intensiﬁed preconditioning
treatment may be desirable for patients with a high tumor
burden.
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